duration of prednisolone thrapy in ITP
Not Applicable
Completed
- Conditions
- ITP.immune thrombocytopenic purpura
- Registration Number
- IRCT201109147553N1
- Lead Sponsor
- Arak university of medical sciences and health services
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 66
Inclusion Criteria
ITP with thrombocytopenia and normal CBC and normal peripheral blood smear.
exclusion criteria: secondary ITP due to some diseases such as: lupus, antiphospholipid syndrom,CLL and infections.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Platelet count. Timepoint: monthly till 6 months after treatment course. Method of measurement: CBC-Diff. and Plt. count/micro liter.
- Secondary Outcome Measures
Name Time Method Blood pressure. Timepoint: before and after treatment course. Method of measurement: via sphygmomanometer. mm.Hg.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie prednisolone's efficacy in immune thrombocytopenic purpura (ITP) pathogenesis?
How does 2-week vs. 3-week prednisolone therapy compare to standard 4-6 week corticosteroid regimens for ITP in terms of platelet response and relapse rates?
Which biomarkers (e.g., TPO, CD20, cytokine profiles) predict treatment response to short-term corticosteroid therapy in adult-onset ITP patients?
What are the differential adverse event profiles of 2-week and 3-week prednisolone protocols in ITP management, including adrenal suppression and osteoporosis risks?
How do TPO receptor agonists or anti-CD20 agents like romiplostim and rituximab complement corticosteroid duration strategies in chronic ITP treatment algorithms?